[go: up one dir, main page]

CY1124664T1 - Υποδοχεις τ λεμφοκυτταρων - Google Patents

Υποδοχεις τ λεμφοκυτταρων

Info

Publication number
CY1124664T1
CY1124664T1 CY20211100860T CY211100860T CY1124664T1 CY 1124664 T1 CY1124664 T1 CY 1124664T1 CY 20211100860 T CY20211100860 T CY 20211100860T CY 211100860 T CY211100860 T CY 211100860T CY 1124664 T1 CY1124664 T1 CY 1124664T1
Authority
CY
Cyprus
Prior art keywords
tcrs
cells
nucleic acids
mage
lymphocyte receptors
Prior art date
Application number
CY20211100860T
Other languages
English (en)
Inventor
Nicholas TRIBBLE
William Lawrance
Eleanor BAGG
Original Assignee
Adaptimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Limited filed Critical Adaptimmune Limited
Publication of CY1124664T1 publication Critical patent/CY1124664T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με υποδοχείς Τ λεμφοκυττάρων (TCR) οι οποίοι δεσμεύουν το ΗLΑ-Α*0201 πεπτίδιο περιορισμού GVYDGREHTV (SEQ ID NO: 1) το οποίο προκύπτει από την πρωτεΐνη MAGE-A4. Οι TCR της εφεύρεσης επιδεικνύουν εξαιρετικά προφίλ ειδικότητας για αυτόν τον επίτοπο MAGE. Παρέχονται επίσης νουκλεϊκά οξέα τα οποία εγκωδικεύουν τους TCR, κύτταρα τα οποία έχουν υποβληθεί σε γενετική μηχανική ώστε να παρουσιάζουν τους TCR, κύτταρα τα οποία φέρουν διαβιβαστές έκφρασης οι οποίοι εγκωδικεύουν τους TCR και φαρμακευτικές συνθέσεις οι οποίες συνίστανται στους TCR, στα νουκλεϊκά οξέα ή στα κύτταρα της εφεύρεσης.
CY20211100860T 2016-04-08 2021-10-05 Υποδοχεις τ λεμφοκυτταρων CY1124664T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606177 2016-04-08
PCT/EP2017/058580 WO2017174824A1 (en) 2016-04-08 2017-04-10 T cell receptors

Publications (1)

Publication Number Publication Date
CY1124664T1 true CY1124664T1 (el) 2022-07-22

Family

ID=58701592

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100860T CY1124664T1 (el) 2016-04-08 2021-10-05 Υποδοχεις τ λεμφοκυτταρων

Country Status (25)

Country Link
US (5) US11286289B2 (el)
EP (2) EP3440106B1 (el)
JP (2) JP7240176B2 (el)
KR (2) KR102523449B1 (el)
CN (2) CN116217703A (el)
AU (2) AU2017248122B2 (el)
BR (1) BR112018070625A2 (el)
CA (1) CA3020058A1 (el)
CY (1) CY1124664T1 (el)
DK (1) DK3440106T3 (el)
ES (1) ES2891321T3 (el)
HR (1) HRP20211493T1 (el)
HU (1) HUE056433T2 (el)
IL (1) IL262128B2 (el)
LT (1) LT3440106T (el)
MX (2) MX395611B (el)
PL (1) PL3440106T3 (el)
PT (1) PT3440106T (el)
RS (1) RS62623B1 (el)
RU (1) RU2018138838A (el)
SG (1) SG11201808751SA (el)
SI (1) SI3440106T1 (el)
SM (1) SMT202100564T1 (el)
WO (1) WO2017174824A1 (el)
ZA (2) ZA201806866B (el)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA49157A (fr) 2014-12-23 2021-06-02 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
SG11201808750PA (en) 2016-04-08 2018-11-29 Adaptimmune Ltd T cell receptors
PT3440106T (pt) 2016-04-08 2021-09-29 Adaptimmune Ltd Recetores de células t
MX2018012265A (es) 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
CA3139011A1 (en) * 2019-05-08 2020-11-12 Medigene Immunotherapies Gmbh Engineered t cells
EP3986938A4 (en) * 2019-06-18 2023-06-28 Regeneron Pharmaceuticals, Inc. Mage-a4 t cell receptors and methods of use thereof
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
CA3150818A1 (en) 2019-08-13 2021-02-18 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily
EP4076666A1 (en) 2019-12-18 2022-10-26 F. Hoffmann-La Roche AG Antibodies binding to hla-a2/mage-a4
CA3164706A1 (en) * 2020-01-14 2021-07-22 Jonathan David SILK Method of treatment of cancer or tumour
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
GB202006903D0 (en) * 2020-05-11 2020-06-24 Adaptimmune Ltd Modified iPSCs
MX2022014636A (es) 2020-05-19 2023-02-23 Amgen Inc Construcciones de unión a mageb2.
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2022233285A1 (en) 2021-03-09 2023-10-19 Cdr-Life Ag Mage-a4 peptide-mhc antigen binding proteins
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
CA3236237A1 (en) * 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
GB202205572D0 (en) 2022-04-14 2022-06-01 Adaptimmune Ltd Engineered T cells
PE20250157A1 (es) 2022-04-21 2025-01-22 Gilead Sciences Inc Compuestos de modulacion de kras g12d
CN119384415A (zh) 2022-07-01 2025-01-28 吉利德科学公司 Cd73化合物
CN120202015A (zh) 2022-09-14 2025-06-24 Cdr-生物科技股份有限公司 Mage-a4肽双重t细胞衔接子
WO2024077134A1 (en) * 2022-10-05 2024-04-11 Tscan Therapeutics, Inc. Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof
EP4598569A1 (en) * 2022-10-05 2025-08-13 Tscan Therapeutics, Inc. Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
KR20250167002A (ko) 2023-04-11 2025-11-28 길리애드 사이언시즈, 인코포레이티드 Kras 조절 화합물
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0869943A1 (en) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
US6710172B1 (en) 1998-10-02 2004-03-23 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
ATE290020T1 (de) 2001-08-31 2005-03-15 Avidex Ltd Löslicher t zell rezeptor
KR100467944B1 (ko) 2002-07-15 2005-01-24 엘지.필립스 엘시디 주식회사 반사투과형 액정표시장치 및 그의 제조방법
RU2355703C2 (ru) 2002-10-09 2009-05-20 Медиджен Лимитед Одноцепочечные рекомбинантные т-клеточные рецепторы
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
KR101130597B1 (ko) * 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산
US20120009162A1 (en) * 2009-04-03 2012-01-12 Masaki Yasukawa T cell receptor and nucleic acid encoding the receptor
BR112013006718B1 (pt) 2010-09-20 2021-12-07 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
WO2012054825A1 (en) 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
PT2755997T (pt) 2011-09-15 2018-10-30 Us Health Recetores de célula t que reconhecem mage restrito a hlaa1 ou hla-cw7
EA201400447A1 (ru) * 2011-10-14 2014-09-30 Тева Фармасьютикал Австралия Пти Лтд. АНТИТЕЛА К CD1d
WO2014164553A1 (en) 2013-03-13 2014-10-09 Imaginab, Inc. Antigen binding constructs to cd8
GB201417803D0 (en) 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
HK1246151A1 (zh) 2015-05-28 2018-09-07 凯德药业股份有限公司 为t细胞疗法而调理患者的方法
KR20250089563A (ko) 2015-10-20 2025-06-18 카이트 파마 인코포레이티드 T 세포 요법을 위한 t 세포를 제조하는 방법
CN106749620B (zh) 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
PT3440106T (pt) 2016-04-08 2021-09-29 Adaptimmune Ltd Recetores de células t
MX2018012265A (es) 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
SG11201808750PA (en) 2016-04-08 2018-11-29 Adaptimmune Ltd T cell receptors
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
MX2019010972A (es) 2017-03-15 2019-12-02 Hutchinson Fred Cancer Res Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
WO2020049496A1 (en) 2018-09-05 2020-03-12 Glaxosmithkline Intellectual Property Development Limited T cell modification

Also Published As

Publication number Publication date
IL262128B2 (en) 2025-11-01
JP2019513383A (ja) 2019-05-30
ZA201806866B (en) 2021-04-28
AU2017248122A1 (en) 2018-11-22
LT3440106T (lt) 2021-12-10
CN109476725B (zh) 2023-04-04
US11286289B2 (en) 2022-03-29
SMT202100564T1 (it) 2022-01-10
MX2022011309A (es) 2022-10-07
SI3440106T1 (sl) 2022-02-28
RU2018138838A (ru) 2020-05-14
PL3440106T3 (pl) 2022-01-31
KR20190065190A (ko) 2019-06-11
WO2017174824A1 (en) 2017-10-12
EP3440106A1 (en) 2019-02-13
HRP20211493T1 (hr) 2022-01-21
JP7577149B2 (ja) 2024-11-01
HUE056433T2 (hu) 2022-02-28
US11725040B2 (en) 2023-08-15
CA3020058A1 (en) 2017-10-12
AU2017248122B2 (en) 2022-07-21
SG11201808751SA (en) 2018-11-29
JP2023081949A (ja) 2023-06-13
US20250084146A1 (en) 2025-03-13
US12180260B2 (en) 2024-12-31
RS62623B1 (sr) 2021-12-31
PT3440106T (pt) 2021-09-29
EP3440106B1 (en) 2021-09-01
US20190127436A1 (en) 2019-05-02
DK3440106T3 (da) 2021-10-04
MX395611B (es) 2025-03-25
ZA202006432B (en) 2025-03-26
US20220031753A1 (en) 2022-02-03
MX2018012269A (es) 2019-05-30
NZ747974A (en) 2024-12-20
KR102523449B1 (ko) 2023-04-19
IL262128B1 (en) 2025-07-01
CN116217703A (zh) 2023-06-06
RU2018138838A3 (el) 2020-07-30
KR20230044016A (ko) 2023-03-31
EP3988565A1 (en) 2022-04-27
AU2022256177A1 (en) 2022-11-24
BR112018070625A2 (pt) 2019-02-05
AU2022256177B2 (en) 2025-03-20
CN109476725A (zh) 2019-03-15
US20230028573A1 (en) 2023-01-26
US11572400B1 (en) 2023-02-07
IL262128A (en) 2018-11-29
JP7240176B2 (ja) 2023-03-15
US20240218043A1 (en) 2024-07-04
KR102747867B1 (ko) 2024-12-30
ES2891321T3 (es) 2022-01-27

Similar Documents

Publication Publication Date Title
CY1124664T1 (el) Υποδοχεις τ λεμφοκυτταρων
CY1121962T1 (el) Υποδοχεις τ κυτταρου
CY1125347T1 (el) Ειδικοι σε κλαουδινη-18.2 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων
CY1124091T1 (el) Βελτιωμενο πολυπεπτιδικο μοριο διπλης ειδικοτητας
CY1124997T1 (el) Καινοτομοι υποδοχεις τ-κυτταρων και ανοσοθεραπεια με την χρηση των ιδιων
CY1122720T1 (el) Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii
EA201992536A1 (ru) Tcr и пептиды
MX2018012268A (es) Receptores de celulas t.
MX2018012265A (es) Receptores de celulas t.
CY1122509T1 (el) Πολυπεπτιδια χιμαιρικου παραγοντα viii και χρησεις αυτων
NZ731571A (en) T cell receptors
CY1119647T1 (el) Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων
MX2018003062A (es) Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
CO2018013471A2 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco
CY1116301T1 (el) Ποντικοι adam6
CY1120471T1 (el) Αντισωματα κατα του cd70
PE20191648A1 (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza
EA202090652A1 (ru) T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras
MX2017006865A (es) Receptores de células t de kras anti-mutado.
MX2016015383A (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
AR095432A1 (es) Proteínas de unión a antígeno
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
EA201892217A1 (ru) Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων